A mutant of pseudorabies virus with deletion of glycoprotein gIII gene prepared from a Japanese isolate: It fails to agglutinate mouse erythrocytes

Yamada, Shunji; Imada, Tadao; Shimizu, Mitsugu; Miura, Yasuo

doi:10.1016/0378-1135(94)00132-g

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Bartha strain of PRV has a mutation in the signal sequence of the gC gene causing a defect in glycosylation and export [235]. Hemagglutinating activiQr has been associated with gC and antibodies against gC have been shown to be hemagglutination-inhibiting [303].…”

Section: Glycoproteinsmentioning

confidence: 99%

Evaluation of vaccinia vectored vaccines expressing glycoproteins gB, gC or gD of pseudorabies virus

Brockmeier

View full text Add to dashboard Cite

This study evaluated vaccinia-vectored vaccines expressing glycoproteins gB, gC, or gD of pseudorabies virus (PRV) in pigs. The vaccines are based on an attenuated vaccinia virus strain, NYVAC, which has reduced virulence and replicative capacity for certain species, including swine. The recombinant vaccinia vaccines were unable to prevent replication of virulent pseudorabies virus or latency but they were able to decrease the amount of virus shed after challenge and decrease clinical signs. In particular, pigs vaccinated with the recombinants expressing either gB or gD were protected at a level comparable to an inactivated PRV virus that was given for comparison. No lesions or clinical signs were seen following vaccination in these studies and no seronegative pigs in contact with vaccinia-vaccinated pigs ever seroconverted. No significant increase in protection occured by giving recombinants expressing multiple glycoproteins and there was no virus neutralizing antibody response or protection induced when the recombinant vaccines were given orally or intranasally. The response to the recombinants is dose dependent but there was no indication that prior immunity to the vaccinia parent virus had any inhibitory effect on subsequent vaccination with these recombinants. The gB recombinant, but not the gD recombinant, was able to stimulate an active immune response in piglets with passive immunity fix)m PRV or NYVAC/gD vaccinated dams. The NYVACyPRV recombinant vaccines were compatible with differential serologic tests currently on the market We could not demonstrate significant cell-mediated immune responses after vaccination with the recombinant vaccines but they may prime this type of response. In summary, the NYVAC/PRV recombinant vaccines afforded protection comparable with that of PRV vaccines currentiy on the market, were safe, and offer some advantages over currentiy available vaccines such as elimination of attenuated PRV viral strains, better induction of immunity in the presence of passive immunity, and more sensitive differential testing capabilities.

show abstract

Section: Glycoproteinsmentioning

confidence: 99%

Evaluation of vaccinia vectored vaccines expressing glycoproteins gB, gC or gD of pseudorabies virus

Brockmeier

View full text Add to dashboard Cite

show abstract

Proteomic analysis of host cellular proteins co-immunoprecipitated with duck enteritis virus gC

Chen

Zheng

Hua

et al. 2021

Journal of Proteomics

View full text Add to dashboard Cite

A mutant of pseudorabies virus with deletion of glycoprotein gIII gene prepared from a Japanese isolate: It fails to agglutinate mouse erythrocytes

Cited by 2 publications

References 16 publications

Evaluation of vaccinia vectored vaccines expressing glycoproteins gB, gC or gD of pseudorabies virus

Evaluation of vaccinia vectored vaccines expressing glycoproteins gB, gC or gD of pseudorabies virus

Proteomic analysis of host cellular proteins co-immunoprecipitated with duck enteritis virus gC

Contact Info

Product

Resources

About